Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GDRXNASDAQ:LFSTNASDAQ:OMCLNASDAQ:RVNC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGDRXGoodRx$4.54+10.5%$4.24$3.68▼$9.26$1.62B1.161.39 million shs3.49 million shsLFSTLifeStance Health Group$5.72-2.7%$6.23$4.64▼$8.61$2.22B1.221.60 million shs1.26 million shsOMCLOmnicell$31.24-1.4%$29.93$22.66▼$55.75$1.46B0.78573,617 shs757,433 shsRVNCRevance Therapeutics$3.65$3.65$2.30▼$6.65$381.02M0.93.43 million shsN/AOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGDRXGoodRx+0.74%+7.59%-5.73%-9.87%-51.93%LFSTLifeStance Health Group+0.68%0.00%+2.62%-15.40%+4.07%OMCLOmnicell+2.19%+4.90%+22.41%-11.29%+6.59%RVNCRevance Therapeutics0.00%0.00%0.00%0.00%+35.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGDRXGoodRx3.1106 of 5 stars3.32.00.00.02.42.51.9LFSTLifeStance Health Group2.1113 of 5 stars3.41.00.00.02.22.50.6OMCLOmnicell3.9543 of 5 stars4.35.00.00.02.21.71.3RVNCRevance Therapeutics2.5688 of 5 stars3.10.00.04.70.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGDRXGoodRx 2.64Moderate Buy$6.5544.17% UpsideLFSTLifeStance Health Group 2.83Moderate Buy$8.5048.60% UpsideOMCLOmnicell 2.57Moderate Buy$44.8343.51% UpsideRVNCRevance Therapeutics 2.13Hold$8.45131.51% UpsideCurrent Analyst Ratings BreakdownLatest OMCL, GDRX, LFST, and RVNC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025LFSTLifeStance Health GroupUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$8.505/23/2025OMCLOmnicellPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/23/2025OMCLOmnicellBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$30.00 ➝ $34.005/23/2025OMCLOmnicellWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$35.00 ➝ $37.005/14/2025OMCLOmnicellWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$31.00 ➝ $35.005/13/2025GDRXGoodRxUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.00 ➝ $5.255/9/2025GDRXGoodRxThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.00 ➝ $5.005/7/2025OMCLOmnicellBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$62.00 ➝ $40.005/7/2025OMCLOmnicellWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$38.00 ➝ $31.004/29/2025GDRXGoodRxWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.004/17/2025OMCLOmnicellWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$40.00 ➝ $38.00(Data available from 6/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGDRXGoodRx$797.41M2.03$0.39 per share11.77$1.93 per share2.35LFSTLifeStance Health Group$1.28B1.73N/AN/A$3.77 per share1.52OMCLOmnicell$1.14B1.29$2.41 per share12.95$26.84 per share1.16RVNCRevance Therapeutics$234.04M1.63N/AN/A($1.73) per share-2.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGDRXGoodRx-$8.87M$0.08N/A25.222.46-2.05%5.35%2.51%8/6/2025 (Estimated)LFSTLifeStance Health Group-$186.26M-$0.10N/AN/AN/A-7.90%-6.66%-4.51%8/14/2025 (Estimated)OMCLOmnicell$12.53M$0.46115.7125.197.531.13%3.82%2.07%7/30/2025 (Estimated)RVNCRevance Therapeutics-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%8/6/2025 (Estimated)Latest OMCL, GDRX, LFST, and RVNC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025GDRXGoodRx$0.04$0.09+$0.05$0.03$202.25 million$202.97 million5/6/2025Q1 2025OMCLOmnicell$0.16$0.26+$0.10-$0.15$260.18 million$269.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGDRXGoodRxN/AN/AN/AN/AN/ALFSTLifeStance Health GroupN/AN/AN/AN/AN/AOMCLOmnicellN/AN/AN/AN/AN/ARVNCRevance TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGDRXGoodRx0.705.485.48LFSTLifeStance Health Group0.191.321.32OMCLOmnicell0.131.371.22RVNCRevance TherapeuticsN/A4.123.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGDRXGoodRx63.77%LFSTLifeStance Health Group85.50%OMCLOmnicell97.70%RVNCRevance Therapeutics97.70%Insider OwnershipCompanyInsider OwnershipGDRXGoodRx4.53%LFSTLifeStance Health Group3.20%OMCLOmnicell2.52%RVNCRevance Therapeutics5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGDRXGoodRx950357.17 million365.25 millionOptionableLFSTLifeStance Health Group6,640388.88 million357.39 millionOptionableOMCLOmnicell3,80046.84 million45.09 millionOptionableRVNCRevance Therapeutics500104.39 million99.07 millionOptionableOMCL, GDRX, LFST, and RVNC HeadlinesRecent News About These CompaniesBrokerages Set Revance Therapeutics, Inc. (NASDAQ:RVNC) Target Price at $8.45June 3, 2025 | americanbankingnews.comRevance Names New CEO to Drive Next Phase in Aesthetic InnovationMay 23, 2025 | globalcosmeticsnews.comRevance Announces Leadership Succession Plan to Support Next Phase of Growth and InnovationMay 21, 2025 | finance.yahoo.comCrown Laboratories Now Operates Under the Name RevanceMarch 31, 2025 | finance.yahoo.comJohnson City-based Crown Labs now operating as ‘Revance’March 31, 2025 | wjhl.comREVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmMarch 6, 2025 | globenewswire.comClass Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & KorsinskyMarch 4, 2025 | accessnewswire.comLevi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RVNCMarch 4, 2025 | accessnewswire.comRVNC DEADLINE TODAY: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action – RVNCMarch 4, 2025 | accessnewswire.comContact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)March 4, 2025 | globenewswire.comContact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)March 4, 2025 | accessnewswire.comRevance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNCMarch 4, 2025 | accessnewswire.comFINAL REMINDER RVNC DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Revance Therapeutics, Inc. Investors to Participate in the Class Action LawsuitMarch 4, 2025 | accessnewswire.comInvestors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNCMarch 4, 2025 | prnewswire.comInvestors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNCMarch 3, 2025 | accessnewswire.comMarch 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNCMarch 3, 2025 | accessnewswire.comRVNC DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action – RVNCMarch 3, 2025 | globenewswire.comClass Action Filed Against Revance Therapeutics, Inc. (RVNC) - March 4, 2025 Deadline to Join - Contact Levi & KorsinskyMarch 3, 2025 | accessnewswire.comDeadline Soon: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud LawsuitMarch 3, 2025 | businesswire.comRevance Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – RVNCMarch 3, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOMCL, GDRX, LFST, and RVNC Company DescriptionsGoodRx NASDAQ:GDRX$4.54 +0.43 (+10.46%) Closing price 04:00 PM EasternExtended Trading$4.58 +0.04 (+0.99%) As of 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.LifeStance Health Group NASDAQ:LFST$5.72 -0.16 (-2.72%) Closing price 04:00 PM EasternExtended Trading$5.90 +0.18 (+3.15%) As of 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.Omnicell NASDAQ:OMCL$31.24 -0.44 (-1.39%) Closing price 04:00 PM EasternExtended Trading$31.24 +0.01 (+0.02%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.Revance Therapeutics NASDAQ:RVNC$3.65 0.00 (0.00%) As of 02/6/2025Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock Hits All-Time Highs: Smart Buy or FOMO Trap? These 3 Stocks Could Be Back in Play Before You Know It Qualcomm: What Monday’s Jump Tells Us About the Stock's Prospects Government Mandate Sends eVTOL Stocks Flying Meta Pulls Ahead of the Mag 7: Analysts Predict a Breakout Year ASML’s AI Edge: How Its EUV Tech Is Creating a New Monopoly Robinhood Drops on S&P Snub—Is a Bigger Pullback Coming? 3 Tightly-Held Growth Stocks Set Up for Short Squeezes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
